Postherpetic neuralgia pregabalin

An excellent example for an enzymatic resolution process is reported for production of Pregabalin. This drug was approved by the US Food and Drug Administration (FDA) in 2004 against neurophatic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. Several different routes have been developed based on asymmetric hydrogenation, crystallization and biocatalytic resolutions [16-20]. The most powerful and currently applied process is based on a lipase resolution, shown in Figure 14.3. This process is one of the very few... 

Pregabalin is approved for the adjunctive treatment of partial seizures, with or without secondary generalization controlled clinical trials have documented its effectiveness. It is available only in oral form, and the daily dose ranges from 150 to 600 mg/d, usually in two or three divided administrations. Pregabalin is also approved for use in neuropathic pain, including painful diabetic peripheral neuropathy and postherpetic neuralgia. 

For postherpetic neuralgia, pregabalin can decrease concomitant opiate use... 

Efficacy and safety of 5% lidocaine medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy. Clin DrugInvestig2009 29 2 il-241. 

---